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The Molecular Adsorbent Recirculating System (MARS) represents an attractive artificial liver support
system for the treatment of liver insufficiency. However, neither indications for MARS treatment (i.e., af-
ter extended liver resection) nor criteria for discontinuation of therapy have been evaluated. Therefore, we
analyzed the clinical data of all our surgical patients who received MARS treatment for acute liver failure
(n 5 7). The aim of the study was to identify prognostic indicators for survival. Four of 174 patients re-
sected for hepatic malignancy at our institution received a total of 13 MARS treatments. Two additional
patients were successfully bridged to orthotopic liver transplantation with seven MARS treatments and
one patient was MARS supported after liver transplantation of a steatotic graft with three MARS treat-
ments. Five of the seven patients survived and were dismissed an average of 31 days, ranging from 17
to 47 days, after the final MARS treatment. No technical complications or adverse effects were observed
during the MARS treatments. Important prognostic factors for hepatic recovery and survival were indo-
cyanin green plasma disappearance rates greater than 5%/min and an increase in clotting factor V levels
after each MARS treatment. We conclude that MARS therapy can be an effective treatment of postoper-
ative liver insufficiency in the surgical hepatobiliary unit. ( J GASTROINTEST SURG 2005;9:1155–
1162)  2005 The Society for Surgery of the Alimentary Tract
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tions that are required for removal of primary or sec-
ondary liver tumors in humans. Excellent hepatic
regeneration and an uncomplicated recovery can be
expected with a 50% or greater remnant of total liver
mass that corresponds to at least 1.2% of body
weight (BW).1–3 More extensive hepatectomies, such
as resections of 50–70% of total liver mass, that leave
smaller liver remnants can result in impaired regen-
eration. The minimum liver remnant needed for sur-
vival in patients is currently considered to be 0.8% of
BW.1,4–6
Synthetic activity and detoxification capacity of
the regenerating liver may fail, typically on the third
to fourth day after surgery, when extended hepatic
resections result in critically low remnant liver005 The Society for Surgery of the Alimentary Tract
lished by Elsevier Inc.mass.6 In these clinical circumstances the Molecular
Adsorbent Recirculating System (MARS; Gambro
Rostock AG, Rostock, Germany) represents an at-
tractive artificial liver support system for the treat-
ment of the acute liver insufficiency.7–10 MARS
uses a hollow-fiber dialysis module containing an al-
bumin-impregnated polysulfone membrane that sep-
arates the patient’s blood and the 20% albumin
dialysate in the extracapillary compartment. The al-
bumin dialysate is cleansed from water-soluble tox-
ins by passage through a hemodialysis module, and
albumin-bound toxins are removed by perfusion
over activated charcoal and resin.11
Reports on the use of MARS for the treatment of
hepatic failure after major liver resection are scarce
and only 12 patients from five different groups havePresented at the Forty-Sixth Annual Meeting of The Society for Surgery of the Alimentary Tract, Chicago, Illinois, May 14–18, 2005 (oral
presentation).
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Gastrointestinal Surgeryso far been described.9,12–15 The reported patient
mortality rate was 75% (9/12). Similarly, reports
on the outcome of MARS therapy in the liver trans-
plant setting, such as bridging to orthotopic liver
transplantation (OLT), treatment of primary non-
function after OLT, or therapy of delayed graft
function after OLT, are limited to single re-
ports.9,11,16–21
Neither clear indications for the postoperative ini-
tiation of MARS treatment, such as after major he-
patic resections, nor criteria for discontinuation of
therapy have been evaluated. Therefore, we prospec-
tively analyzed clinical data from all of our surgicalpatients who received MARS treatment. The aim
of the study was to identify prognostic parameters
for survival during MARS therapy.
MATERIAL AND METHODS
The clinical data obtained from the surgical pa-
tients (n 5 7) who were included in the study are
summarized in Table 1. Informed consent for MARS
treatment was obtained from the patients or an im-
mediate family member (institutional approval:
1.05.01.30.-17). Indications for the initiation ofTable 1. Patient Characteristics, Diagnosis, Surgical Treatment, and Outcome After MARS Treatment
Patient
(Gender,
Age [yr]) Group Diagnosis
Surgical
Intervention
(Resected
Couinaud
Liver
Segments)
Indication for
Initiation
of MARS
Treatment
MARS
Cycles (n)
MARS-Responder?
Comment on
Clinical Course
1 (F, 30) Group A Cholangiocarcinoma Extended left
hepatectomy
(I, II, III, IV,
V, VIII)
Factor
V !30%
3 Yes; discharged
17 days after MARS
Hepatic vein
reconstruction
2 (M, 65) Group A Cholangiocarcinoma Extended left
hepatectomy
(II, III, IV,
part. V,
part. VIII)
Factor
V !30%
3 Yes; discharged
31 days after MARS
Hepatic artery
reconstruction
3 (M, 48) Group B Gallbladder
carcinoma
Extended left
hepatectomy
(I, II, III,
IV, V, part. VIII)
Asterixis 2 No; died 1 day after
discontinuation
of MARS
4 (M, 64) Group B Hepatocellular
carcinoma in
cirrhosis
(hemochromatosis)
Extended right
hepatectomy
(part. IV, V,
VI, VII, VIII)
Asterixis 5 No; died 2 days after
discontinuation
of MARS
5 (F, 66) Group B Late-onset hepatic
failure in
autoimmune
hepatitis
OLT Asterixis 6 No; bridge to OLT.
discharged 45
days after OLT
6 (M, 34) Group B Primary
non-function
after OLT
Re-OLT Factor
V!30%
1 No; bridge to
re-OLT.
discharged 17
days after re-OLT
7 (F, 65) Group A Delayed graft
function
after OLT
(steatotic graft)
OLT Asterixis 3 Yes; discharged
47 days after MARS
OLT 5 orthotopic liver transplantation; Part. 5 partially resected liver segment.
Group A includes all MARS responding and surviving patients. Group B contains all MARS nonresponding patients (nonsurvivors and patients
successfully bridged to orthotopic liver transplantation).
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encephalopathy and asterixis in four of the patients
and clotting factor V levels below 30% in three intu-
bated patients.
MARS Therapy
A central venous access was established by intro-
ducing a Mahurkar dual-lumen catheter (Tyco
Healthcare Switzerland Ltd., Wollerau, Switzer-
land). Patients were then connected to the primed
MARS monitor (Gambro Rostock AG) that was op-
erated in conjunction with a Fresenius 4000S (Bad
Homburg, Germany) dialysis machine. A standard
dialysate containing dextrose was used at a rate of
500 ml/min with sodium concentrations slightly
above 140 mmol/L and a bicarbonate concentration
of 35 mmol/L. Patient blood and albumin flow rates
within the MARS monitor were adjusted between
150 and 250 ml/min. Heparin was administered to
maintain activated clotting time (ACT) between
100 and 180 seconds. MARS treatment was limited
to a maximum of 8 hours, followed by a 16-hour
MARS-free interval.
Laboratory Parameters
Liver function tests including coagulation param-
eters, complete blood cell count, serum electrolytes,
ammonia, and creatinine were determined before
and after each MARS treatment. Indocyanin green
(ICG) plasma disappearance rates (ICG-PDR) were
measured after injection of 0.5 mg ICG/kg body
weight (ICG-Pulsion; Pulsion Medical Systems, Mu-
nich, Germany) by the use of the noninvasive LI-
MON monitor (Pulsion Medical Systems).
Patient Groups
Two patient groups, based on the hepatic re-
sponse under MARS therapy, were compared to
identify potential prognostic factors during MARS
therapy (Table 1). The two groups were MARS res-
ponders (group A, surviving patients after extended
liver resections and with delayed function of a stea-
totic liver graft; n 5 3; 9 MARS cycles) and MARS
nonresponders (group B, nonsurvivors and patients
bridged to OLT; n 5 4; 14 MARS cycles).
Statistical Analysis
Results are expressed as mean 6 SD. Data were
statistically analyzed using the Jandel Scientific Soft-
ware (1.0; Jandel Scientific, San Raffael, CA). t-Tests
were used to compare normally distributed data be-
tween groups, and paired t-test analysis was per-
formed to compare laboratory parameters beforeand after MARS treatment. For nonnormally distrib-
uted data, a Mann-Whitney rank sum test was ap-
plied to compare groups and the Wilcoxon signed
rank test was used for paired analysis. The signifi-
cance level was set at P ! 0.05.
RESULTS
During the study period, 212 hepatic resections
were performed in 174 patients at our institution.
Only 4 patients of the 20 with extended liver resec-
tions required MARS support. Three (5.4%) of a to-
tal of 56 OLT patients received pretransplant or
posttransplant MARS therapy.
Two patients from group A (n 5 3), after under-
going extended hepatic resection, were treated daily
for 3 days beginning on postoperative day 2. One pa-
tient with a delayed graft function after OLT re-
ceived three MARS cycles 3 days post-OLT on.
These three patients were discharged from the hos-
pital 17, 31, and 47 days after MARS.
One patient from group B (n 5 4), after a right
portal branch occlusion and a consecutive extended
right hepatectomy due to hepatocellular carcinoma
(HCC) in a cirrhotic liver (hemochromatosis), was
treated from day 7 to day 11. MARS was then dis-
continued because of a lack of clinical improvement.
The patient died 2 days later. An extended left hep-
atectomy and right portal vein reconstruction were
performed in one patient with gallbladder carcinoma.
MARS treatment was initiated on postoperative day
2 and discontinued after two cycles to comply with
the patient’s request upon receiving histopathologic
confirmation of a hepatic tumor remnant. The pa-
tient died 1 day later. Two patients in this group
were successfully bridged to OLT and re-OLT and
discharged 17 and 45 days after MARS treatment.
Ten of 23 MARS therapies lasted the full 8 hours.
The other 13 MARS treatments were discontinued
early (6.3 6 1.5 hours) due to a filter obstruction.
No differences in therapy time were observed be-
tween groups A and B. An average blood flow of
188 6 19 ml/min and corresponding albumin flow
in the MARS monitor of 2376 19 ml/min were used
in both groups (P 5 NS between groups). No ad-
verse effects were encountered during the 166 hours
of MARS therapy.
The average heparin dose administered during
MARScycleswas 5306375 IE/hr in groupAand, sig-
nificantly lower, 1206 160 IE/hr (P! 0.05), in group
B. A trend toward higher heparin doses with every ad-
ditional MARS cycle was detected in group A. Most
important, except for two minor bleeding incidents
at the catheter insertion site, no severe bleeding com-
plications were observed.
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Score
Initial MELD scores22 added up to 19, 19, and 31
in group A and 15, 22, 40, and 40 in group B. MELD
scores significantly (P ! 0.001) decreased (23.9 6
2.2) in group A after MARS treatment; they were un-
changed (P 5 NS) in group B (20.9 6 2.8).
Laboratory Parameters
Hemoglobin values and leukocyte counts did not
differ between the groups, nor did MARS therapy al-
ter these values. Initial platelet counts were similar in
both groups (Table 2). A paired analysis revealed sig-
nificant platelet loss during MARS treatment in
group B (P ! 0.05). Water-soluble creatinine and
ammonia were efficiently (P ! 0.05) removed by
MARS therapy. Bilirubin and alkaline phosphatase
levels were significantly higher (P ! 0.05) in group
B patients. Bilirubin levels only decreased in group
B (P ! 0.05) during the MARS therapy.
Coagulation Parameters
One patient in group A and two patients in group
B received fresh frozen plasma (FFP) before MARS
therapy. Clotting parameters obtained within 24
hours after FFP administration were excluded from
analysis.International normalized ratio (INR) values were
significantly lower (P ! 0.05) in group A both be-
fore and after MARS treatment (Table 2). In a paired
analysis, INR values increased during MARS therapy
(P ! 0.05) in group B while they were unaltered in
group A (P5NS). All group A patients had INR val-
ues below 2.0 at all time points. It should be noted
that only patients of group B received FFP during
MARS therapy.
Initial clotting factor V levels were 24.7 6 7.5%
in group A and 21.8 6 21.5% in group B. Factor
V levels increased significantly (P ! 0.05) between
MARS cycles in group A by 12.2 6 8.0% and the av-
erage factor V levels decreased by 0.4 6 6.1% in
group B (P5NS) (Fig. 1). All patients who had clot-
ting factor V levels spontaneously reach greater than
40% during MARS therapy recovered.
Noninvasive Measurement of ICG-PDR
ICG-PDRs were obtained before and after MARS
treatment. Values remained stable throughout
MARS cycles (P 5 NS). Average ICG-PDRs for
group A patients were 7.06 1.1%/min. Correspond-
ing values for group B were significantly lower (2.5
6 1.1%/min, P ! 0.0001) (Fig. 2). No patient with
an ICG-PDR below 5.0%/min survived without
OLT.Table 2. Laboratory Parameters of Surgical Patients With Liver Failure Before and After MARS Therapy
Laboratory Parameters
Group A (n 5 3)
(9 MARS Cycles)
Group B (n 5 4)
(14 MARS Cycles)
Thrombocytes (109/L) Pre-MARS 101.4 6 51.0 87.5 6 61.4
Post-MARS 95.6 6 43.2 64.2 6 47.6*
Creatinine (mmol/L) Pre-MARS 143.3 6 57.7 181.8 6 139.5
Post-MARS 100.3 6 30.5* 141.5 6 115.0*
Ammonia (mmol/L) Pre-MARS 37.9 6 31.4 45.2 6 37.7
Post-MARS 26.2 6 18.6* 35.9 6 28.9*
Aspartate aminotransferase (U/L) Pre-MARS 2151 6 2178 1408 6 1633
Post-MARS 1254 6 1077 1007 6 1024
Alanine aminotransferase (U/L) Pre-MARS 2534 6 2713 1080 6 1083
Post-MARS 1804 6 1859 932 6 1020
Alkaline phosphatase (U/L) Pre-MARS 75 6 31 258 6 113†
Post-MARS 76 6 29 227 6 95†
Bilirubin (mmol/L) Pre-MARS 115.1 6 76.0 264.8 6 176.7†
Post-MARS 96.4 6 60.3 216.4 6 119.0*†
Prothrombin time (INR) Pre-MARS 1.44 6 0.26 2.22 6 0.45†
Post-MARS 1.41 6 0.26 2.66 6 0.78*†
Average serum laboratory parameters (mean6 SD) of MARS responding patients (group A) and MARS nonresponding patients (group B) before
(Pre-) and after (Post-) MARS therapy are presented. A significant decrease (*P! .05) of thrombocyte counts was seen in group B after MARS
therapy. This indicated platelet loss during treatment. Creatinine and ammonia levels in the blood decreased after MARS in both groups as
expected. Significant differences (†P! .05) between groups A and B were detected in alkaline phosphatase, bilirubin, and INR values. In a paired
anlaysis comparing values before and after MARS treatment, a significant decrease in bilirubin values (*P ! .05) and a rise of INR (*P ! .05)
values was seen in group B only.
Vol. 9, No. 8
2005 MARS Treatment in Surgical Patients 11590
10
20
30
40
50
60
70
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
Cl
ot
tin
g 
fa
ct
or
 V
 le
ve
ls 
(%
)
Re-OLT
 
OLT
Recovery 
†
†
MARS MARS MARS MARS MARS 
Fig. 1. Clotting factor V levels in patients with liver failure during MARS therapy. Depicted are clotting
factor V levels of all patients during the entire period of MARS therapy (MARS, arrow). Three patients
received fresh frozen plasma (FFP) ( ) before the initiation of MARS therapy. Only group B patients
received FFP during MARS treatment. After superurgent listing for OLT, one patient received six
FFP treatments on day 5. Initial factor V levels were !30% in six of seven patients. Surviving patients
(bold line; Recovery) showed an increase of factor V levels with each additional MARS cycle (a MARS
cycle includes 8 hours of MARS treatment followed by 16 hours MARS free). Two patients died ( fine
line; †) after discontinuation of MARS treatment. Two patients (dotted line) were successfully bridged to
OLT and re-OLT.DISCUSSION
MARS therapy has proved to be safe for the treat-
ment of liver failure in over 3000 patients.9 However,
the reported mortality for MARS-treated surgical
patients with hepatic failure after major liver resec-
tion has been reported at 75%.9,13–15 Patient selec-
tion for liver surgery and the indications for MARS
treatment clearly influence the survival data. Com-
plete tumor resection resulted in a small-for-size liver
remnant (!0.8% BW) in three of four resected pa-
tients in this series. The remaining resected patient
had hemochromatosis-related liver cirrhosis in the
left liver remnant. To date, no appropriate indicators
have been validated to a priori determine survival of
patients with severe posthepatectomy liver dysfunc-
tion. We therefore initiated MARS therapy in surgi-
cal patients early on, when it was apparent that liver
insufficiency was imminent. MARS treatment was
initiated as soon as asterixis was present or, in the
case of prolonged mechanical ventilation and com-
plete muscle relaxation, when clotting factor V levels
were below 30%. Similarly, we suggest the early use
of MARS9,11,16,17 as a bridge to OLT, for the treat-
ment of primary nonfunction after OLT, and as
a temporary support strategy after transplantation
of a steatotic liver graft.Several prognostic parameters correlated well
with survival in this analysis. ICG-PDR values have
been used for the past 20 years to monitor hepatic
function after injury,23 to assess liver function before
and during major hepatic resections,24 and to deter-
mine suitability as well as early graft dysfunction in
the liver transplant setting.25,26 In our study, ICG-
PDRs remained low, less than 10%/min, despite sig-
nificant clinical and synthetic improvement in the
group A patients during the first days of liver sup-
portive therapy. Noninvasive ICG-PDR monitoring
seems inappropriate for the verification of successful
hepatic regeneration early but was clearly able to in-
dicate patients survival if an ICG-PDR greater than
5%/min was determined (Fig. 2). The values ob-
served are considerably lower than those described
in critically ill patients with hepatic dysfunction.27,28
The role for ICG-PDR in evaluating surgical pa-
tients requires further prospective investigation.
Interestingly, INR and bilirubin values also corre-
lated well with survival. They may contain a predic-
tive value not only in the setting of chronic (MELD
score)22 but also in acute postoperative liver failure.
Interestingly, the described7 significant decrease in
serum bilirubin levels during MARS therapy was ob-
served only in group B.
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Gastrointestinal SurgeryClotting factor V levels can predict the outcome
in acute liver failure and coagulopathy.29 For this
reason we systematically assessed factor V levels be-
fore and after each MARS treatment. Factor V levels
acted as a surrogate marker for synthetic hepatic ac-
tivity, and we noted a significant increase between
each MARS cycle in patients of group A that indic-
ated an early improvement in liver function (Fig. 1).
The alterations in systemic heparin response and
variations in heparin clearance rates in acute liver
disease are well recognized.30 Additionally, heparin
elimination shows considerable interindividual varia-
tions.31 A recent systematic review of artificial and
bioartificial liver support systems from the Cochrane
Hepato-Biliary group identified bleeding complica-
tions as the most important and serious adverse
events during treatment of hepatic failure.32 There-
fore, we closely monitored ACT values during
MARS therapy. In contrast to other reports,10,15 no
bleeding problems were observed in our series. We
strongly recommend tight control of ACT values
and cautious administration of heparin. Thirteen
MARS Flux Dialyzers were lost during the treatment
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Fig. 2. Indocyanin green plasma disappearance rates (ICG-
PDRs) in surgical patients with liver insufficiency. Tukey
box plot: Depicted are ICG-PDR before (Pre) and after
(Post) MARS treatment of MARS responding patients (group
A) and MARS nonresponding patients (group B). The box
boundaries indicate the 25th and 75th percentiles. The line
inside the box shows the value of the 50th percentile. Capped
bars indicate the 10th and 90th percentiles, and symbols mark
outliers. Patients responding to MARS treatment (group A)
had significantly higher ICG-PDR than nonresponders
(group B). An ICG-PDR of O5.0%/min appears to separate
survivors from nonsurvivors (*P ! 0.0001).of five different patients as a consequence of this pol-
icy. Clotting of the MARS system is a nonreversible
event in our experience. Neither rinsing of the sys-
tem nor additional administration of a heparin bolus
can rescue the filter. In cases of filter obstruction,
and when elevated transmembrane pressure indicates
imminent hemolysis, we reduce the blood and albu-
min perfusion rate and terminate the MARS
treatment.
Our initial experience with MARS treatment of
surgical patients with liver failure shows promising
results with five of seven patients surviving. The ben-
eficial effect of MARS therapy on our surgical pa-
tients is difficult to determine, and the potential
prognostic factors identified in our series as well as
the MARS system itself require further validation in
additional prospective randomized controlled trials.
CONCLUSION
MARS therapy is safe and can be an effective
treatment for postoperative liver insufficiency. An
important prognostic factor for survival identified
in our patients was an ICG-PDR of greater than
5%/min. MARS therapy represents an important
therapeutic option for the treatment of severe hep-
atic dysfunction in the surgical hepatobiliary unit.
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Dr. Jan Stange (Rostock, Germany): The albu-
min dialysis system using MARS was developed as
a detoxification support system to support patients
in liver failure by removing toxins from blood to im-
prove hepatic encephalopathy and lessen the hyper-
dynamic circulation that leads to hypertension and
kidney failure. These items are factors that alter sur-
vival. The majority of data have been collected in pa-
tients with chronic liver disease who have acute liver
failure. Data of postsurgical complications that end
in liver failure are rather rare, and here is what I per-
sonally think is the specific value of your presenta-
tion. In addition to postsurgical liver failure, other
covariants might affect outcome. Knowing aboutthose covariants would help us to assign the therapy
to those patients who would have the biggest benefit
from it.
From your presentation, the cofactors that were
predictive for a good outcome can be divided into
two major groups, the first group having high
INR, high bilirubin, and a low indocyanine green
clearance. The second group had the ability to show
improvement in liver function in the phases between
treatments. So in the group of patients who when off
treatment have recovery of liver function, I have
three questions.
First, with the exception of clotting factors or
INR, your parameters, bilirubin and indocyanine
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What is your personal opinion about postsurgical
biliary complications in predicting outcome?
The second question d we found that a very im-
portant cofactor in dealing with liver failure is, in the
presence of infection developing into sepsis, the suc-
cessful treatment of the sepsis with antibiotics was im-
portant. Can you make any short comment on that?
And the third question is, usually postsurgical liver
failure patients have low blood pressure and prob-
lems with hemodynamics. Usually this requires the
use of continuous kidney support. For liver support,
we don’t know whether continuous or intermittent
might be preferable. Was your specific intention to
use intermittent treatments?
Dr. Inderbitzin: The answer to the first
question d we treated all patients between day 2
and 3 after resection. So they were still in the phase
of small liver remnant size. So these patients do have
a problem with their hepatocellular mass.
Question number 2 about sepsis d we are trying
to start treatment early and it is too early for septic
complications. Septic complications are a contraindi-
cation in our clinic to start the MARS treatment be-
cause we are not sure about what we remove and we
might even harm the septic patient with a MARS
treatment. That might change in the future.
The third question was about hemodynamics. All
patients were hemodynamically stable and they didnot change during MARS treatment. The specific
reason we chose 8 hours and intermittent treatment
is that our team cannot handle the 24 hours that are
also suggested by your group. That might be the fu-
ture, but for the beginning, an intermittent treat-
ment was more practical.
Dr. Steven Curley (Houston, TX): I have two
questions for you. To follow up a little bit on the
question that was asked previously, you presented
seven patients. That is seven patients out of how
many total who had an extended resection during
the time you have been doing this?
Number 2, do you routinely calculate the future
liver remnant on your patients to know if you are go-
ing to have a patient who may be at risk for liver in-
sufficiency, and should those patients have portal
vein embolization prior to their resection?
Dr. Inderbitzin: In the same period of time we
performed 212 liver resections, including 24 exten-
ded resections that were comparable to the ones
that required MARS therapy. There were four pa-
tients after resection and three patients were peri-
OLT. I used the peri-OLTs as baseline of no liver
function.
Unfortunately, we did not receive the liver volume
from our radiologist that would allow us to deter-
mine the presence of a small liver remnant before
resection. We do use the portal vein embolization.
We used it in one of the described patients to induce
liver regeneration.
